Track regulatory status, clinical trials, and published research across three jurisdictions.
Compound status overview
185+ compounds tracked across 3 jurisdictions
Research Landscape
Featured Compound
GLP-1 Receptor Agonist
Semaglutide is a once-weekly injection (sold as Ozempic for diabetes and Wegovy for weight management) or daily tablet (Rybelsus for diabetes) that mimics GLP-1, a natural gut hormone that controls blood sugar and appetite. It has become one of the most widely discussed medications in the world, with clinical trial data spanning over 50,000…
Regulatory Timeline
FDA ORIG 1
FDA SUPPL 1
FDA ORIG 1
FDA SUPPL 4
FDA SUPPL 3
FDA SUPPL 1
FDA SUPPL 8
FDA SUPPL 6
Latest Articles
The FDA's accelerated approval framework permits market entry for peptide therapeutics based on surrogate or intermediate endpoints, provided sponsors fulfill mandatory post-approval confirmatory obligations. This pathway is not a reduced evidentiary standard but an evidence-adaptive mechanism designed to address unmet medical needs while managing residual uncertainty. Understanding its specific application to peptides—where immunogenicity, manufacturing consistency, and biomarker validation int
Receptor selectivity profiling sits at the heart of preclinical peptide evaluation, determining whether a compound's binding profile supports further development or signals unacceptable off-target liability. Radioligand displacement, fluorescence polarization, and cell-based functional assays each illuminate different dimensions of selectivity, yet each carries methodological constraints that can obscure cross-reactivity risks. Understanding how to interpret fold-selectivity ratios, dose-respons
Exenatide and liraglutide represent two distinct structural strategies for GLP-1 receptor agonism, each achieving FDA approval through rigorous clinical development. Their pharmacokinetic engineering and regulatory pathways offer a detailed blueprint for understanding how preclinical design principles translate into approved therapeutics. This article examines the mechanistic and structural foundations of both compounds and how they inform ongoing research into next-generation GLP-1 peptides.
Clinical Trial Spotlight
Tirzepatide
Eli Lilly has announced positive topline results from its Phase III SUMMIT trial evaluating tirzepatide in patients with heart failure with preserved ejection fraction and obesity. The trial met its primary endpoint demonstrating statistically significant improvement in heart failure symptoms.
Trials by phase
Platform at a Glance
185
Compounds
13,277
Clinical Trials
1,288
Recruiting
447,212
Publications
Latest updates
New research publications for Glucagon
New research publications for Semaglutide
News & updates
10 new publications found on PubMed for Glucagon. Total publications: 53594 (animal: 18168, human: 28015, in vitro: 4267, reviews: 9544).
Read more →5 new publications found on PubMed for Semaglutide. Total publications: 4420 (animal: 206, human: 2550, in vitro: 98, reviews: 1251).
Read more →5 new publications found on PubMed for Tirzepatide. Total publications: 1861 (animal: 59, human: 1005, in vitro: 34, reviews: 662).
Read more →11 new publications found on PubMed for Vancomycin. Total publications: 39599 (animal: 3111, human: 24521, in vitro: 5236, reviews: 4143).
Read more →15 new publications found on PubMed for Glucagon. Total publications: 53582 (animal: 18166, human: 28005, in vitro: 4267, reviews: 9540).
Read more →9 new publications found on PubMed for NAD+ (Peptide-Adjacent). Total publications: 45902 (animal: 14655, human: 14516, in vitro: 5337, reviews: 4179).
Read more →13 new publications found on PubMed for VIP. Total publications: 24218 (animal: 7788, human: 11889, in vitro: 1762, reviews: 7287).
Read more →8 new publications found on PubMed for P21. Total publications: 40511 (animal: 8496, human: 24857, in vitro: 9912, reviews: 1573).
Read more →